Current Understanding of the Role of PPAR𝛾 in Gastrointestinal Cancers

Table 1

Some of the clinical trials on the role of PPARγ ligands on CRC.

Authors	Drug used	Number of patients	Combined treatment	Tumors	Effect
Tepmongkol et al.	Rosiglitazone	23	Radioiodine	Thyroid carcinoma	Responded
Hau et al.	Pioglitazone	14	Capecitabine/Temozolomide and Rofecoxib	Glioma	Partial response
Kebebew et al.	Rosiglitazone	10	Radioiodine	Thyroid carcinoma	Responded
Schwartz et al.	LY293111	38	No	Solid tumors	No response
Baetz et al.	Ly293111	28	Irinotecan	Solid tumors	No response
Demetri et al.	Troglitazone	3	No	Liposarcoma	Responded
Smith et al.	Rosiglitazone	106	No	Prostate carcinoma	No response
Tenenbaum et al.	Bezafibrate	3011	No	Colon cancer	Responded
Read et al.	Rosiglitazone	23	Bexarotene	Solid tumor	No response
Debrock et al.	Rosiglitazone	12	Pretreatment	Liposarcoma	negative
Burstein et al.	Troglitazone	22	Prechemotherapy or Prehormonal	Breast cancer	No response
Kulke et al.	Troglitazone	25	No	Colon cancer	No response
Mueller et al.	Troglitazone	41	Preandrogen deprivation	Prostate cancer	No response